Deciphering the genetic alterations in matrix metallo-proteinase gene family and its putative association with head and neck squamous cell carcinoma

Jambukeswaran Aparna¹, Aseervatham Selvi Smiline-Girija¹, Arumugam Paramasivam², Jayaseelan Vijayashree-Priyadharsini²*

1) Department of Microbiology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai 600077, India
2) Biomedical Research Unit and Laboratory Animal Centre-Dental Research Cell, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai 600077, India

ABSTRACT

Matrix metallo-proteinases (MMPs) a group of zinc-dependent proteolytic enzymes which play a key role in tumorigenesis by degrading almost all extracellular matrix (ECM) components. MMPs are associated with tumour progression including invasion, angiogenesis, metastasis and poor prognosis. Genetic alterations such as single nucleotide variations and other gross chromosomal abnormalities have been found to drive the process of malignant transformation. In line with the above facts, the present study aims to analyse the genetic alterations, associated gene expression patterns and survival probability of HNSCC patients upon differential expression of the crucial members of the MMP family. The observational study utilised several computational tools. The cBioportal database was used as the primary source of identification of genetic alterations in the MMP family of genes. The Cancer Gene Atlas dataset (Firehose Legacy) was used for the investigations. The highest frequency of alteration was identified in the MMP20 gene (8%). The common gene alterations were amplifications, deep deletions, mis-sense and truncating mutations. Interestingly, amplification and deep deletion followed the same pattern in about 31 patients, in genes MMP1, 3, 7, 8, 10, 12, 20, and 27. The MMP20 gene expression analysis showed a significant difference between the normal subjects and the patients with primary tumors (6.95 x 10^-4). The Kaplan-Meier survival curve analysis identified that female patients with high-level expression of the MMP20 gene had a low survival probability when compared to male HNSC patients. Taken together, the present study provides preliminary information about the involvement of the MMP20 gene of the MMP family with HNSCC. Further experimental analysis is required to derive a strong association between the gene alterations observed with HNSCC.

Keywords: Matrix metalloproteinases; head and neck squamous cell carcinoma; survival
INTRODUCTION

Head and neck squamous cell carcinoma is the most common form of cancer with a mortality rate of 40-50%. HNSCC stands sixth among the cancer types [1], with an increased incidence clustered in certain geographical regions such as the south Asian countries including India, Pakistan and Srilanka [2]. The risk factors associated with the disease are smoking and usage of smokeless tobacco such as pan, gutka etc., alcoholism, infections with human papilloma virus (HPV), poor oral hygiene, sharp tooth and other environmental factors. Several genetic markers have been identified to be associated with the process of tumorigenesis in HNSCC. In recent years studies on extracellular matrix proteins have gained interest due to their involvement in cell growth, survival, differentiation and motility. The local degradation of ECM enables tumor cells to metastasize from the tumor site to other organs. Matrix metalloproteinases are enzymes which are responsible for the breakdown of ECM. The MMP family consist of 23 genes, which have been implicated in the tumor invasion and progression [3]. They belong to zinc dependent ECM remodelling endopeptidase possessing the ability to degrade components of ECM [4]. The gene expression of MMPs is regulated by growth factors, stress, oncogenic transformations and cell-cell interactions. The responsive members of the MMP family of genes contain activator protein-1 (AP-1) binding site at the proximal promoter site. The proto-oncogene Jun and Fos bind to the AP-1 element which in turn activates the transcription of the MMP gene [5,6].

A study by Nandha et al, demonstrated that regulation of matrix metalloproteinases of types MMP2 and MMP9 could aid in understanding the invasive potential of tumors. Clinicopathology, histopathology and TNM grading were performed on tumor and adjacent normal tissues. Zymography, immuno-histochemistry, ELISA, western-blot and real time PCR were used to assess the enzyme activity. A differential expression pattern of several genes were observed. An increased level of MMP9 was accompanied by an increase in fibronectin, protein kinase B, focal adhesion kinase, phosphatidylinositol 3-kinase and reduced expression of tissue inhibitor of metalloproteinase-1. Thus it was proved that MMP9 has a vital role to play in tumor invasion and metastasis and hence can be used as a marker to demonstrate the metastatic potential of tumors [7]. Alterations or aberrations in genes encoding proteins involved in the process of tumorigenesis could act as important biomarkers to identify the risk or susceptibility of an individual to develop HNSCC [8]. Several studies performed earlier were based on differential gene expression analysis, which revealed the association of those genes with HNSCC. The rationale of the present study was to identify genetic variants in the MMP family of genes and to deduce the possible consequences of such alterations in the development of HNSCC. In addition, the study also throws light on the differential expression profile of the gene carrying the highest frequency of alterations along with an observation on the survival probability of the altered gene.

MATERIALS AND METHODS

The present study follows a retrospective observational study design. The source of patient’s data was procured from the cBioportal database. This database hosts an exhaustive collection of patient’s details from different cohorts (Table 1). The TCGA, Firehose legacy data set consisted of 528 head and neck squamous cell carcinoma cases of which sequencing and copy number alteration data were available for 512 tumor samples. A complete profile of mutated, amplified, deleted genes was available for each of the cases in the dataset. The demographic details of the cases in the dataset have been provided in Table 1. A list of vital genes related to the MMP family was obtained from the "HUGO Gene Nomenclature Committee at the European Bioinformatics Institute" (www.genenames.org/data/) database [9]. User defined queries based on these genes were submitted in the cBioportal database and the resultant Oncoprint data was used for further analysis [10, 11].
Oncoprint data analysis: The Oncoprint data provides information on the frequency distribution of variations in each of the genes selected, type of variation, changes in the protein coding amino acids, gene amplification, deletions, insertions, frameshifts, splice site mutations etc. These details can be used to (a) derive a putative association between the disease phenotype and genotype, (b) identify the variations in less understood pathways or genes, and (c) identify any novel variations which can be associated with the disease phenotype [10, 11].

| Gender | Male (n = 386) | Female (n = 142) |
|--------|---------------|-----------------|
| Mutation count | 6-3181 | |
| Diagnosis age | 19-90 years | |
| Smoking status | Data not available: 12 | Unknown: 1 |
| Alcohol history | Yes-352 | No-165 |
| Neoplasm Histologic grade | Grade 1: 63 | Grade 2: 311 |
| Race category | White: 452 | African: 48 |

Note: Data obtained from the cBioportal site.

Gene expression and survival curve analysis: The expression of the gene in HNSCC was analysed using the UALCAN (http://ualcan.path.uab.edu/cgi-bin/TCGA-survival1.pl?) database. Survival curve analysis based on the tumor grade and expression profile was performed to demonstrate the putative role of Rho family genes with HNSC. Gene expression data is expressed as transcripts per million (TPM) which is a normalization method for RNA-seq data. The TPM values used for the generation of box-whisker plots were also used to determine the significant difference between the groups. The t test was performed using PERL script with the comprehensive perl archive network (CPAN) module. Combined survival effect analysis of gene expression and other clinical parameters such as race, gender, tumor grade, cancer subtypes were assessed using multivariate Kaplan-Meier survival analysis [12].

RESULTS

Computational approach is considered to be the most widely used method by researchers because of its ease of use. An exhaustive screening could be performed using these platforms. A specific pathway or a candidate gene can be analyzed for its association with disease phenotype. The preliminary results obtained from such studies can be employed for screening of the population which could result in identification of lead molecules for the purpose of diagnosis or therapy [13, 14]. Hence in the present study the cBioportal and UALCAN database were used to
assess the genetic alterations and gene expression in the HNSCC dataset. The primary database, cBioportal which hosts several datasets of which the TCGA dataset (TCGA, Firehose Legacy) was selected for the present study. The TCGA dataset consisted of 528 HNSCC patients (530 samples). The male:female ratio was found to be 2.7:1, with the diagnostic age groups ranging from 19-90 years. The number of individuals with the history of smoking and alcohol was roughly around 98% (515 individuals) and 67% (352 individuals). The dataset had samples from patients of American (85.6%), African (9.1%), Asian (2.1%) and American Indian (0.4%) descent. The distribution of patients based on the histologic grade of neoplasm is given in Table 1, of which 59% of patients had grade 2 tumor.

The analysis of oncoprint data which was obtained after submission of a query for 23 genes of the MMP family demonstrated alterations ranging from 0.2 - 8%. The MMP23A and MMP28 were the only genes which did not show any kind of alterations among HNSC patients. Several non-synonymous and truncating mutations of unknown significance were identified in the present study (Table 2). Interestingly, about 31 HNSC patients presented with similar gene amplification and deep deletion in genes MMP1, 3, 7, 8, 10, 12, 20 and 27. The frequency of non-synonymous mutation count was found to be high in MMP13 and MMP18 genes. Further, gene expression analysis was carried out for the gene which showed the highest frequency of gene alteration i.e., MMP20 [8%] (Fig. 1).

Table 2: Details on the proteins encoded by MMP family of genes. The genetic loci, type and frequency of alterations and variant allele frequency are given in the Table.

| Gene | Protein | Alteration | Loci | % of alteration | Variant allele frequency in tumor sample |
|------|---------|------------|------|-----------------|----------------------------------------|
| MMP1 | Matrix Metallopeptidase 1 (Interstitial Collagenase) | Gene Amplification | 11q22.2 | 7 | |
|      |         | Deep deletion |      |  | F308L 0.29 |
|      |         |              |      |  | L224W 0.07 |
|      |         | Deep deletion |      |  | R214C 0.08 |
|      |         |              |      |  | L11del 0.02 |
|      |         | Deep deletion |      |  | T451M 0.20 |
|      |         |              |      |  | P412H 0.53 |
|      |         | Deep deletion |      |  | A335V 0.0051 |
| MMP2 | Collagenase Type IV-A | Gene amplification | 16q12.2 | 2 | |
|      |         | Deep deletion |      |  | T377A 0.13 |
|      |         |              |      |  | W657R 0.04 |
|      |         | Deep deletion |      |  | E177G 0.22 |
|      |         |              |      |  | S32L 0.16 |
|      |         | Deep deletion |      |  | D142N 0.13 |
| MMP3 | Matrix Metalloproteinase 3 (Stromelysin 1, Progelatinase) | Gene amplification | 11q22.2 | 7 | |
|      |         | Deep deletion |      |  | D124H 0.03 |
|      |         |              |      |  | D170A 0.23 |
| MMP7 | Matrix Metalloproteinase 7 (Matrilysin, Uterine) | Gene amplification | 11q22.2 | 7 | |
|      |         | Deep deletion |      |  | R2Q 0.09 |
| MMP8 | Matrix Metalloproteinase 8 (Neutrophil Collagenase) | Gene amplification | 11q22.2 | 7 | |
|      |         | Deep deletion |      |  | P362S 0.05 |
|      |         |              |      |  | T30A 0.25 |
|      |         | Deep deletion |      |  | N57D 0.28 |
|      |         |              |      |  | W140C 0.06 |
|      |         | Deep deletion |      |  | E200K 0.05 |
| MMP9 | Matrix Metalloproteinase 9 (Gelatinase B, 92kDa Gelatinase, 92kDa Type IV Collagenase) | Gene amplification | 20q13.12 | 0.6 | |
|      |         | Deep deletion |      |  | K356* 0.18 |
| MMP  | Gene Name | Gene Function | Amplification | Deletion | Chromosome | Alleles |
|------|-----------|---------------|---------------|----------|------------|---------|
| MMP10 | Matrix Metalloproteinase 10 (Stromelysin 2) | Gene amplification Deep deletion | 11q22.2 | 7 |  |
| | | | | | H227Y | 0.73 |
| | | | | | P186S | 0.35 |
| | | | | | W314* | 0.07 |
| | | | | | F401L | 0.06 |
| | | | | | G208D | 0.04 |
| | | | | | R116S | 0.46 |
| MMP11 | Matrix Metalloproteinase 11 (Stromelysin 3) | Gene amplification Q205= | 22q11.23 | 1.2 |  |
| | | | | |  |
| MMP12 | Matrix Metalloproteinase 12 (Macrophage Elastase) | Gene amplification Deep deletion K67_splice | 11q22.2 | 6 |  |
| | | | | |  |
| MMP13 | Matrix Metalloproteinase 13 (Collagenase 3) | Gene amplification Deep deletion D429N | 11q22.2 | 7 |  |
| | | | | | G374R | 0.23 |
| | | | | | D128H | 0.13 |
| | | | | | P127S | 0.27 |
| | | | | | G248D | 0.02 |
| | | | | | D147N | 0.06 |
| | | | | | R95T | 0.14 |
| | | | | | M91I | 0.30 |
| MMP14 | Matrix Metallopeptidase 14 (Membrane-Inserted) | Gene amplification Deep deletion S62L | 14q11.2 | 2 |  |
| | | | | | E373D | 0.13 |
| | | | | | F429V | 0.08 |
| | | | | | F467Y | 0.30 |
| MMP15 | Matrix Metallopeptidase 15 (Membrane-Inserted) | Gene amplification Deep deletion A278V | 16q21 | 1.6 |  |
| | | | | | S505Rfs*11 | 0.31 |
| | | | | | V94L | 0.22 |
| | | | | | R120Qfs*2 | 0.08 |
| MMP16 | Matrix Metallopeptidase 16 (Membrane-Inserted) | Gene amplification K339N | 8q21.3 | 6 |  |
| | | | | | R154H | 0.44 |
| | | | | | G215R | 0.13 |
| | | | | | R153C | 0.18 |
| | | | | | E518G | 0.16 |
| | | | | | Y268H | 0.16 |
| | | | | | P313H | 0.36 |
| | | | | | K98N | 0.14 |
| MMP17 | Matrix Metallopeptidase 17 (Membrane-Inserted) | Gene amplificationX98_splice | 12q24.33 | 0.6 |  |
| | | | | | E228K | 0.24 |
| | | | | |  | 0.25 |
| MMP19 | Matrix Metallopeptidase-19 | Gene amplification | 12q13.2 | 0.2 |  |
| | | | | | |  |
| MMP20 | Matrix Metallopeptidase 20 (Enamelysin) | Gene amplification | MMP20 Matrix Metallopeptidase 20 (Enamelysin) |  |
| | | | | | Deep deletion Q374K | 0.33 |
| | | | | | Q267P | 0.26 |
| | | | | | L282V | 0.29 |
| | | | | | L277P | 0.20 |
| | | | | | P293T | 0.25 |
| | | | | | L295R | 0.36 |
| | | | | | E434K | 0.43 |
| MMP21 | Matrix Metallopeptidase 21 | Gene amplification | MMP21 | 10q26.2 |  |
| | | | | | I226N | 0.35 |
| | | | | | H501Y | 0.34 |
| | | | | | H392Q | 0.09 |
### Table 1: Gene Alterations in MMP Family of Genes

| Gene  | Type                          | Alterations                        | Chromosome | Log2 Fold Change |
|-------|-------------------------------|------------------------------------|------------|-----------------|
| MMP23B| Matrix Metalloproteinase 23B  | Gene amplification                 | 1p36.33    | 1.8             |
| MMP24 | Matrix Metalloproteinase 24   | Deep deletion                      | 20q11.22   | 2.6             |
|       | (Femalysin)                   |                                    |            |                 |
| MMP25 | Membrane-Type Matrix Metalloproteinase 6 | Gene amplification | 16p13.3    | 1               |
| MMP26 | Matrix Metalloproteinase-26   | Gene amplification Deep deletion   | 11p15.4    | 1.2             |
|       | (Matriysin 2)                 |                                    |            |                 |
| MMP27 | Matrix Metalloproteinase-27   | Gene amplification Deep deletion   | 11q22.2    | 7               |

**Figure 1:** The Oncoprint data depicts the gene alterations in MMP family of genes. Each of the grey bar represents HNSC patients.

The relative gene expression showed a significant difference between normal and primary HNSC tumor tissue ($p = 6.95 \times 10^{-4}$) (Fig. 2). Also, the comparison of gene expression patterns between different grades of HNSC returned significant values between normal vs grade 2 ($p = 4.84 \times 10^{-4}$), grade 1 vs grade 4 ($p = 4.08 \times 10^{-5}$) and grade 2 vs grade 4 ($p = 1.35 \times 10^{-4}$). The results demonstrated that the level of expression of MMP20 increased with increasing grade of tumor (Fig. 3). The Kaplan–Meier method was used to identify the effect of MMP20 gene expression in male and female subjects with HNSC patient’s survival. The effect of high level expression in female patients and male patients on probability of survival returned a significant $p = 0.036$, wherein a high level expression in female subjects was related to low survival.
probability when compared to male subjects. A p value less than 0.05 is considered to be significant (Fig. 4). The results accumulated provided evidence on the putative association of \textit{MMP20} gene alterations with HNSC.

**Figure 2:** Box-Whisker plot showing relative expression of \textit{MMP20} in primary tumor and normal tissues. The X-axis represents the type of sample and the Y-axis represents the gene expression levels presented as transcript per million. A statistically significant difference was observed between the two groups (p = 6.95 × 10^{-4}).

**Figure 3:** Box-Whisker plot showing relative expression profile of \textit{MMP20} gene in different grades of HNSC. The X-axis denotes the TCGA samples and Y-axis denotes the transcripts per million values. The comparison of gene expression patterns between different grades of HNSC returned significant values between normal vs grade 2 (p = 4.84 × 10^{-4}), grade 1 vs grade 4 (p = 4.08 × 10^{-5}) and grade 2 vs grade 4 (p = 1.35 × 10^{-4}).

**DISCUSSION**

The \textit{MMP20} gene encodes a protein enamelysin required for the normal tooth development. Apart from carryout this function, they are also involved in the breakdown of ECM which forms a part of the normal physiological process such as embryonic development, remodelling of tissues, reproduction etc., Deviations in the expression of proteins have been observed in several pathological conditions such as arthritis and metastasis. Majority of the MMPs are proproteins which are activated upon cleavage by proteinases. The MMP and its cognate the dentin sialophosphoprotein have been known to influence the process of tumorigenesis.

A study conducted by Liu et al, investigated the expression of MMP20 in 33 cases of laryngeal squamous cell carcinoma using real time PCR assay and 73 cases employing immunohistochemistry compared to normal epithelium. The team observed over-expression of MMP20 in LSCC when compared to the adjacent normal tissues, which implies that MMP20 could be used as a prognostic marker for lymph node metastasis [15]. The results of the present study were in agreement with the study conducted by Liu et al, wherein the dentin
sialophosphoprotein (DSPP) and matrix metalloproteinase are known to react in OSCC. In line with this concept, a study was conducted by Nikitakis et al, demonstrated the effects of DSPP/MMP20 gene silencing on the expression of cancer stem cell (CSC) markers. The CSC markers viz., ABCG2 (84%) and CD44 (81%) were found to be downregulated following the double silencing. The results indicate that downregulation of MMP20/DSPP which could aid in the reduction of CSC population [16].

![Figure 4: Kaplan–Meier plots showing the effect of MMP20 gene expression in male and female subjects with HNSC patient’s survival. The x-axis represents time in days and y-axis shows the survival probability. The blue line indicates high level expression in female patients and the red line indicates high level expression of the MMP20 gene in male patients. The effect of gene expression coupled with gender upon survival probability returned a significant p = 0.036. A high level expression in female subjects presented with a low survival probability when compared to male subjects.](image)

The MMP20 expression was considered to be confined to dental hard tissues. A study demonstrated the association of MMP20-DSPP in human OSCC. The expression of MMP20 along with DSPP was assessed in several tumor types of breast, colon, prostate, thyroid and cervical region. The expression pattern was found to be significantly higher in all the malignant tissue types when compared to their normal counterparts. The study also documents that the level of MMP20 increased as the tumor progressed to subsequent stages, thus suggesting that this combination could be a lethal duo in the process of tumorigenesis. A very recent study by Aseervatham and Ogbureke investigated the effect of MMP20-DSPP silencing on several cancer related phenotypes such as epithelial-mesenchymal transition, cell adhesion, angiogenesis and metastasis. The team reported that the expression of certain crucial protein markers viz., MMP2, MMP9, integrins, VEGF was significantly decreased with a concomitant increase in the expression of E-cadherin. Thus these results indicate that the tumorigenic effect of MMP20/DSPP is mediated by the up-regulation of genes potentially involved in steps leading to tumor development, progression and invasion [17, 18].

Mutations in the genes encoding MMPs have shown to exert deleterious effects. Studies pertaining to the association between matrix metallo-proteinases polymorphisms with the risk of oral cancer have provided insights into the importance of human genetic variations upon susceptibility to a genetic disorder. The meta-analysis conducted by Zhang et al, identified the promoter polymorphism in MMP2 gene (-1306 C>T) to be significantly associated with oral and nasopharyngeal cancer. Also, a subgroup analysis based on ethnicity and tumor site identified the polymorphism of the promoter element -1171 5A>6A to be associated with HNSC risk in...
European population [19]. A meta-analysis on the association of risk of oral cancer with MMP polymorphisms had identified MMP-1 (-1607) as a significant genetic marker related to oral cancer risk in Asian and protectiveness in European groups [20]. A similar study by de Matos et al, revealed that the SNP rs2252070 in MMP-13 gene conferred protection against oral and oropharyngeal SCC. Furthermore, the cumulative effects of IL-8 (rs4073), MMP-13 (rs2252070) and two other polymorphisms of MMP-1 (rs2071230, rs470558) in connection with environmental carcinogens, tobacco and alcohol was related to increased risk of oral and oropharyngeal SCC development [21]. A genotyping study conducted by Lin et al., identified the combined effect of environmental factors and polymorphism of the MMP-11 gene to be associated with the susceptibility of OSCC. They observed that patients heterozygous or homozygous for the C allele of MMP-11 (rs738792) polymorphism presented with an increased incidence of lymph node metastasis in comparison to patients homozygous for T allele [22]. Tu et al., demonstrated that polymorphism of MMP-9 C>T although was not associated directly with OSCC or OSF, stratification of case subjects based on median age, found a strong association with the risk of OSCC in young patients (p = 0.0029). Thus, it was concluded that the impact of aging and habits such as areca nut chewing are the influencing factors of OSCC risk [23]. Numerous reports gathered through experimental approaches and meta-analysis have provided substantial evidence on the association of genetic alterations and variations with HNSCC [24].

Acknowledgements: The authors thank the patients who were included in the TCGA study and the developers of cBioportal and UALCAN databases without whom such kind of analysis would have been out of reach for budding researchers.

Conflict of Interest: None.

Funding statement: The authors Dr. Vijayashree Priyadharsini J. and Dr. Paramasivam A. thank the Science and Engineering Research Board (SERB), Government of India for the financial support rendered through the core research grant (CRG) (No. CRG/2019/003756).

REFERENCES

1. Mandal R, Şenbabaoğlu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, Lee KW, Ganly I, Hakimi AA, Chan TA, Morris LG. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 2016;1:e89829.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
3. Huang H. Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances. Sensors (Basel) 2018;18:3249.
4. Yadav L, Puri N, Rastogi V, Satpute P, Ahmad R, Kaur G. Matrix metalloproteinases and cancer - roles in threat and therapy. Asian Pac J Cancer Prev 2014;15:1085-1091.
5. Singh NK, Quyen DV, Kundumani-Sridharan V, Brooks PC, Rao GN. AP-1 (Fra-1/c-Jun)-mediated induction of expression of matrix metalloproteinase-2 is required for 15S-hydroxyeicosatetraenoic acid-induced angiogenesis. J Biol Chem 2010;285:16830-16843.
6. Gupta S, Kumar P, Kaur H, Sharma N, Saluja D, Bharti AC, Das BC. Selective participation of c-Jun with Fra-2/c-Fos promotes aggressive tumor phenotypes and poor prognosis in tongue cancer. Sci Rep 2015;5:16811.
7. Nanda DP, Dutta K, Ganguly KK, Hajra S, Mandal SS, Biswas J, Sinha D. MMP-9 as a potential biomarker for carcinoma of oral cavity: a study in eastern India. Neoplasma 2014;61:747-757.

http://mbrc.shirazu.ac.ir
8. Pereira AC, Dias do Carmo E, Dias da Silva MA, Blumer Rosa LE. Matrix metalloproteinase gene polymorphisms and oral cancer. J Clin Exp Dent 2012;4:e297-e301.
9. Braschi B, Denny P, Gray K, Jones T, Seal R, Tweedie S, Yates B, Bruford E. Genenames.org: the HGNC and VGNC resources in 2019. Nucl Acids Res 2019;47:D786-D792.
10. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larssen E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-404.
11. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobson A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1.
12. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Bababhadrapatruni VS, Varambally S. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 2017;19:649-658.
13. Vijayashree P, Paramasivam A. Virtual screening of mutations in antioxidant genes and its putative association with HNSCC: An in silico approach. Mutat Res 2020;9:111710 [Epub ahead of print].
14. Anita R, Paramasivam A, Vijayashree Priyadharsini J, Chitra S. The m6A readers YTHDF1 and YTHDF3 aberrations associated with metastasis and predict poor prognosis in breast cancer patients. Am J Cancer Res 2020;10,2546-2554.
15. Liu Y, Li Y, Liu Z, Zhang L, Anniko M, Duan M. Prognostic significance of matrix metalloproteinase-20 overexpression in laryngeal squamous cell carcinoma. Acta Otolaryngol 2011;131:769-773.
16. Nikitakis NG, Gkouveris I, Aseervatham J, Barahona K, Ogbureke KUE. DSPP-MMP20 gene silencing downregulates cancer stem markers in human oral cancer cells. Cell Mol Biol Lett 2018;23:30.
17. Aseervatham J, Geetu S, Anunobi CC, Koli K, Ogbureke KUE. Survey of dentin sialophosphoprotein and its cognate matrix metalloproteinase-20 in human cancers. Cancer Med 2019;8:2167-2178.
18. Aseervatham J, Ogbureke KUE. Effects of DSPP and MMP20 Silencing on adhesion, metastasis, angiogenesis, and epithelial-mesenchymal transition proteins in oral squamous cell carcinoma cells. Int J Mol Sci 2020;21:4734.
19. Zhang C, Li C, Zhu M, Zhang Q, Xie Z, Niu G, Song X, Jin L, Li G, Zheng H. Meta-analysis of MMP2, MMP3, and MMP9 promoter polymorphisms and head and neck cancer risk. PLoS One 2013;8:e62023.
20. Li Y, Wang Y, Sun H, Zhang Y, Li H, Cong X, Yin W, Song W. Association between matrix metalloproteinase-1, 2, 3 polymorphisms and oral cancer risk: A meta-analysis. Genet Test Mol Biomarkers 2018;22:456-464.
21. de Matos FR, Santos EM, Santos HBP, Machado RA, Lemos TMAM, Coletta RD, Freitas R. Association of polymorphisms in IL-8, MMP-1 and MMP-13 with the risk and prognosis of oral and oropharyngeal squamous cell carcinoma. Arch Oral Biol 2019;108:104547.
22. Lin CW, Yang SF, Chuang CY, Lin HP, Hsin CH. Association of matrix metalloproteinase-11 polymorphisms with susceptibility and clinicopathologic characteristics for oral squamous cell carcinoma. Head Neck 2015;37:1425-1431.
23. Tu HF, Wu CH, Kao SY, Liu CJ, Liu TY, Lui MT. Functional -1562 C-to-T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male areca users. J Oral Pathol Med 2007;36:409-414.
24. Jain A, Girija A, Arumugam P, Jayaseelan V. A Computational approach to identify the mutations in the genes of the RTK signaling pathway and their possible association with oral squamous cell carcinoma. Middle East J Cancer 2020; [epub ahead of print] doi: 10.30476/mejc.2020.82336.1079.